Prime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine (NASDAQ: PRME), a biotechnology company focused on developing one-time curative genetic therapies, has announced its participation in two major upcoming investor conferences. The company will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 10:30 a.m. ET in New York, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 2:40 p.m. ET in Miami Beach. Both presentations will be available via live audio webcasts on the company's website, with replays accessible for 90 days following each event.
Prime Medicine (NASDAQ: PRME), un'azienda biotecnologica specializzata nello sviluppo di terapie genetiche curative monodose, ha annunciato la sua partecipazione a due importanti conferenze per investitori in programma. La società presenterà alla Jefferies Global Healthcare Conference il 5 giugno 2025 alle 10:30 ET a New York, e alla Goldman Sachs 46th Annual Global Healthcare Conference il 9 giugno 2025 alle 14:40 ET a Miami Beach. Entrambe le presentazioni saranno disponibili in diretta audio streaming sul sito web dell'azienda, con le registrazioni accessibili per 90 giorni dopo ogni evento.
Prime Medicine (NASDAQ: PRME), una empresa biotecnológica enfocada en desarrollar terapias genéticas curativas de una sola vez, ha anunciado su participación en dos importantes conferencias para inversores próximas. La compañía presentará en la Jefferies Global Healthcare Conference el 5 de junio de 2025 a las 10:30 a.m. ET en Nueva York, y en la Goldman Sachs 46th Annual Global Healthcare Conference el 9 de junio de 2025 a las 2:40 p.m. ET en Miami Beach. Ambas presentaciones estarán disponibles a través de transmisiones de audio en vivo en el sitio web de la empresa, con repeticiones accesibles durante 90 días después de cada evento.
Prime Medicine (NASDAQ: PRME)는 일회성 치료 유전자 치료제 개발에 주력하는 생명공학 회사로, 다가오는 두 주요 투자자 컨퍼런스에 참가할 예정임을 발표했습니다. 회사는 2025년 6월 5일 오전 10시 30분(동부시간) 뉴욕에서 열리는 Jefferies Global Healthcare Conference와 2025년 6월 9일 오후 2시 40분(동부시간) 마이애미 비치에서 열리는 Goldman Sachs 46th Annual Global Healthcare Conference에서 발표할 예정입니다. 두 발표 모두 회사 웹사이트를 통해 라이브 오디오 웹캐스트로 제공되며, 각 행사 후 90일 동안 다시보기 서비스를 이용할 수 있습니다.
Prime Medicine (NASDAQ : PRME), une société de biotechnologie spécialisée dans le développement de thérapies génétiques curatives en dose unique, a annoncé sa participation à deux grandes conférences d'investisseurs à venir. L'entreprise présentera lors de la Jefferies Global Healthcare Conference le 5 juin 2025 à 10h30 ET à New York, ainsi qu'à la Goldman Sachs 46th Annual Global Healthcare Conference le 9 juin 2025 à 14h40 ET à Miami Beach. Les deux présentations seront diffusées en direct en audio webcast sur le site internet de la société, avec des rediffusions accessibles pendant 90 jours après chaque événement.
Prime Medicine (NASDAQ: PRME), ein Biotechnologieunternehmen, das sich auf die Entwicklung einmaliger heilender Gentherapien spezialisiert hat, hat seine Teilnahme an zwei bedeutenden bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird auf der Jefferies Global Healthcare Conference am 5. Juni 2025 um 10:30 Uhr ET in New York sowie auf der Goldman Sachs 46th Annual Global Healthcare Conference am 9. Juni 2025 um 14:40 Uhr ET in Miami Beach präsentieren. Beide Präsentationen werden als Live-Audio-Webcasts auf der Unternehmenswebsite verfügbar sein, mit Wiedergaben, die jeweils 90 Tage nach der Veranstaltung abrufbar sind.
- None.
- None.
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences:
- Jefferies Global Healthcare Conference: Fireside chat on Thursday, June 5, 2025, at 10:30 a.m. ET in New York, NY.
- Goldman Sachs 46th Annual Global Healthcare Conference: Fireside chat on Monday, June 9, 2025, at 2:40 p.m. ET in Miami Beach, FL.
Live audio webcasts of each presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. Replays of each webcast will be available on the Prime Medicine website for 90 days following the event.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.
© 2025 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
Investor and Media Contacts
Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com
Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com
FAQ
When is Prime Medicine (PRME) presenting at the Jefferies Global Healthcare Conference 2025?
When is Prime Medicine's presentation at the Goldman Sachs Healthcare Conference 2025?
How long will Prime Medicine's conference webcasts be available for replay?
Where can I access Prime Medicine's conference presentations?
